This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Women's Health  • Cognitive Disorders  • Menopause  • Alert me on articles by topic

Leon J. Thal, MD; Ronald G. Thomas, PhD; Ruth Mulnard, RN, DNSc; Mary Sano, PhD; Michael Grundman, MD, MPH; Lon Schneider, MD

Arch Neurol. 2003;60:209-212.

Objective  To investigate whether an association exists between estradiol and estrone levels and measures of cognitive functioning in women with Alzheimer disease (AD) treated with conjugated equine estrogen (Premarin; Wyeth-Ayerst, Philadelphia, Pa).

Methods  We studied 120 postmenopausal women who underwent hysterectomy and who had AD treated with Premarin for 1 year. Plasma estradiol and estrone levels were determined at multiple points during the 1-year treatment trial. The change from baseline level at 2 and 12 months was associated with the change score on 7 different assessments of cognitive functioning.

Results  At baseline, estradiol levels were low and there were no associations between the estradiol level and the 7 neuropsychological measures. A similar pattern was observed for estrone treatment. During treatment with 0.625 mg/d of Premarin, estradiol levels increased about 4-fold; while receiving 1.25 mg/d of Premarin, estradiol levels increased about 8-fold. A similar pattern was seen with estrone treatment. For both estradiol and estrone levels, there were no significant associations between the change in plasma level and the change in neuropsychological test scores at either 2 or 12 months.

Conclusion  Although Premarin elevated estradiol and estrone levels, there was no association between hormone levels and cognitive functioning after either 2 or 12 months of treatment.

From the Departments of Neurosciences (Drs Thal and Grundman) and Family and Preventive Medicine (Dr Thomas), University of California, San Diego, School of Medicine, La Jolla; Veterans Affairs San Diego Healthcare System, San Diego, Calif (Dr Thal); Institute for Brain Aging and Dementia, University of California, Irvine (Dr Mulnard); Sergievsky Center, Columbia University, New York, NY (Dr Sano); and the Departments of Psychiatry and Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Dr Schneider).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations
GLEASON et al.
Ann. N. Y. Acad. Sci. 2005;1052:93-115.
ABSTRACT | FULL TEXT  

Methodological Issues in Estrogen Treatment Trials for Alzheimer's Disease
MULNARD
Ann. N. Y. Acad. Sci. 2005;1052:173-181.
ABSTRACT | FULL TEXT  

Benefits and Risks of Sex Hormone Replacement in Postmenopausal Women
Seelig et al.
J. Am. Coll. Nutr. 2004;23:482S-496S.
ABSTRACT | FULL TEXT  

The Effect of Genetic Differences and Ovarian Failure: Intact Cognitive Function in Adult Women with Premature Ovarian Failure Versus Turner Syndrome
Ross et al.
J. Clin. Endocrinol. Metab. 2004;89:1817-1822.
ABSTRACT | FULL TEXT  

Parity, Number of Pregnancies, and the Age of Onset of Alzheimer's Disease
Sobow and Kloszewska
J. Neuropsychiatry Clin. Neurosi. 2004;16:120-121.
FULL TEXT